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Emphysema and idiopathic pulmonary fibrosis (IPF) present either per se or coexist in com-
bined pulmonary fibrosis and emphysema (CPFE). Serum surfactant proteins (SPs) A, B, C
and D levels may reflect lung damage. We evaluated serum SP levels in healthy controls,
emphysema, IPF, and CPFE patients and their associations to disease severity and
survival.
Methods
122 consecutive patients (31 emphysema, 62 IPF, and 29 CPFE) and 25 healthy controls
underwent PFTs, ABG-measurements, 6MWT and chest HRCT. Serum levels of SPs were
measured. Patients were followed-up for 1-year.
Results
SP-A and SP-D levels differed between groups (p = 0.006 and p<0.001 respectively). In
post-hoc analysis, SP-A levels differed only between controls and CPFE (p<0.05) and
CPFE and emphysema (p<0.05). SP-D differed between controls and IPF or CPFE
(p<0.001 for both comparisons). In IPF SP-B correlated to pulmonary function while SP-A,
correlated to the Composite Physiological Index (CPI). Controls current smokers had higher
SP-A and SP-D levels compared to non-smokers (p = 0.026 and p = 0.023 respectively).
SP-D levels were higher in CPFE patients with extended emphysema (p = 0.042). In
patients with IPF, SP-B levels at the upper quartile of its range (26 ng/mL) presented a
weak association with reduced survival (p = 0.05).
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Conclusion
In conclusion, serum SP-A and SP-D levels were higher where fibrosis exists or coexists
and related to disease severity, suggesting that serum SPs relate to alveolar damage in
fibrotic lungs and may reflect either local overproduction or overleakage. The weak associa-
tion between high levels of SP-B and survival needs further validation in clinical trials.
Introduction
Pulmonary emphysema and idiopathic pulmonary fibrosis (IPF) are two distinct entities
defined by different clinical, functional, radiological, and pathological criteria [1]. IPF is the
most common of the idiopathic interstitial lung diseases (i-ILDs) and has the histopathologic
and/or radiologic pattern of usual interstitial pneumonia (UIP) [2], while emphysema is
defined as an enlargement of the air spaces distal to the terminal bronchioles due to the
destruction of tissues forming their walls [3]. These two entities coexist in a condition charac-
terized by upper lobe emphysema and lower lobe pulmonary fibrosis, which is known as
combined pulmonary fibrosis and emphysema (CPFE) [1, 4]. The coexistence of the two condi-
tions, which have different pathophysiological and functional characteristics, results in the
development of a disease entity, with distinct clinical and functional characteristics and differ-
ent prognosis compared to its individual components [5].
Pulmonary surfactant is a highly surface-active mixture of proteins and lipids that is syn-
thesized and secreted onto the alveoli by type II epithelial cells [6, 7]. The protein part of sur-
factant constitutes of four types of surfactant proteins (SP), SP-A, SP-B, SP-C and SP-D.
SP-A and SP-D are hydrophilic proteins that regulate surfactant metabolism and have immu-
nologic functions, whereas SP-B and SP-C are hydrophobic molecules, which play a direct
role in the organization of the surfactant structure in the interphase and in the stabilization
of the lipid layers during the respiratory cycle [8, 9]. Different polymorphisms of SP-A [10],
and SP-B [10–13] genes and mutations in SP-C [14] genes have been related to COPD. Fur-
thermore, studies have shown that circulating SP-A and SP-D levels were increased in
patients with COPD compared to normal smokers and non-smoking controls and correlated
to airway obstruction [15–17]. On the other hand, there is evidence showing a possible role
of surfactant proteins in the development of ILDs. Infants and children with mutations in the
genes encoding surfactant proteins develop such a disease early in their life [18], while muta-
tions of SP-A and C genes are associated with familial interstitial lung disease [19–23]. Serum
levels of SP-D have been shown to be higher in patients with IPF compared to control sub-
jects [24, 25]. Furthermore, serum SP-D concentrations are related to the annual rate of dete-
rioration of pulmonary function [26], while high serum levels of SP-A and SP-D seem to be
predictors of rapid disease deterioration and have been associated with poor survival in
patients with IPF [25, 27, 28, 29]. Finally, there is evidence than SP-C gene mutations are
associated with CPFE [30–33], while SP-D has been reported to correlate to pulmonary func-
tion in these patients [34].
According to the above, we hypothesized that in patients with CPFE, SP would be more
disturbed in comparison to patients with only IPF and patients with only emphysema in a
clinically significant way. The aim of the present study was to evaluate serum levels of Surfac-
tant Proteins (A, B, C and D) in patients with CPFE, emphysema only, IPF only, and healthy
controls and to test their possible associations to pulmonary function, disease severity, and
survival.
Surfactant Proteins in CPFE
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Methods
Subjects
From February 2013 to December 2014 we enrolled 147 consecutive patients (31 with emphy-
sema, 62 with IPF, and 29 with CPFE) and 25 healthy controls (smokers and non-smokers).
All study subjects were in stable condition and did not report any exacerbation or respiratory
tract infection during the last 8 weeks. Patients with α1-antitrypsin deficiency, connective tissue
disease at the time of diagnosis of CPFE, diagnosis of other interstitial lung disease (such as
drug induced ILDs, pneumoconiosis, hypersensitivity pneumonitis, sarcoidosis, pulmonary
histiocytosis, LAM, and eosinophilic pneumonia), patients unable to perform PFTs, as well as
patients with inability or unwillingness to collaborate with the investigators were not included
in the study. All subjects were followed up for one year and their vital status has been recorded.
Study design
All patients provided a detailed history upon arrival, and underwent physical examination and
blood samples collection. Subsequently they were submitted to pulmonary function tests, mea-
surement of body mass index (BMI) and evaluation of exercise capacity using the 6 minutes
walking test. Arterial blood gases were also measured. Finally, all patients underwent high reso-
lution computed tomography of the chest (HRCT). The study protocol was approved by the
ethics committee of “Attikon” University Hospital, Chaidari Athens Greece and all patients
gave written informed consent.
Pulmonary Function Tests
Pulmonary function tests (PFTs) were performed with commercially available system (Master
Screen, Erich Jaeger GmbH, Wuerzburg, Germany) and included post-bronchodilator forced
expiratory volume in one second (FEV1), FVC, FEV1/FVC ratio, total lung capacity (TLC),
residual volume (RV), inspiratory capacity (IC) and diffusing capacity for carbon monoxide
(DLCO). Diffusing capacity for carbon monoxide (DLCO) and diffusing capacity for carbon
monoxide adjusted for alveolar volume (DLCO/VA) were assessed by means of the single breath
method with the patient in the sitting position. Lung function measurements were expressed as
percentages of predicted values. Tests were performed according to the American Thoracic
Society guidelines [35] by the same technician in order to ensure consistency of the results.
The composite physiologic index that is associated to mortality in IPF and CPFE [36] was
[calculated according to the following formula: 91.0—(0.65 x percent predicted diffusing
capacity for carbon monoxide [DLCO])—(0.53 x percent predicted FVC) + (0.34 x percent
predicted FEV1)][37] was determined in all subjects [38]. In all patients, arterial blood samples
were taken for the measurement of PaO2 and PaCO2 using a commercially available blood gas
analyzer (model 1630; Instrumentation Laboratories, Milan Italy)
HRCT
All patients underwent HRCT using Brilliance CT 64-channel scanner (Philips, Eindhoven, the
Netherlands). Scans were performed with 1–1.5mm section thickness and a 1–2 sec scanning
time during breath holding at end inspiration. Films were read by a radiologist with expertise
in HRCT who was blinded to the rest of the measurements. The degree of emphysema and/or
fibrosis was calculated using a visual score as previously described [39, 40], using a five-point
scale based on the percentage of lung involved: 0: no emphysema/fibrosis; 1: up to 25% of the
lung parenchyma involved; 2: between 26–50% of lung parenchyma involved; 3: between 26–
75% of the lung parenchyma involved; and 4 between 76–100% of lung parenchyma involved.
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Grades of the axial images of each lung were added and divided by the number of images evalu-
ated to yield emphysema and/or fibrosis scores that ranged from 0 to 4 [39, 40]. The percentage
of destructed lung area (%DLA) was obtained by summing %emphysema and %fibrosis [41].
The presence of emphysematous lesions15% (i.e. score0.6) of the pulmonary parenchyma
in CPFE patients was considered as significant [42, 43]
Assessment of Dyspnea and Exercise Capacity
Dyspnea was assessed with the modified (5-point) Medical Research Council (MRC) dyspnea
scale, as previously described [44]. Exercise capacity was measured with the 6 minutes walk test
in a 100 ft corridor, according to the ATS guidelines [45]. The distance walked in 6 minutes,
difference in dyspnea according to Borg scale and alterations in oxygen saturation were
recorded in each patient.
Blood Samples Collection and Measurements of Surfactant Proteins
Blood samples were collected from each subject and were immediately centrifuged at 1500g for
15 min at 4°C and the supernatant (serum) was stored at -80°C until measurements.
Serum surfactant proteins were measured using commercially available enzyme-immuno-
sorbent assay (ELISA) kits (SP-A, SP-B and SP- C, USCN Life Science, China and, SP-D, Bio-
ventor, Germany) according to the manufacturer's protocol. The lower limits of detection were
the following: SP-A: 8.2 pg/mL, SP-B: 0.31 ng/ml, SP-C: 0.112 ng/mL and SP-D: 0.01 ng/mL.
Statistical analysis
Normality of distributions was checked with Kolmogorov-Smirnov test. Comparisons between
groups were performed with Kruskal-Wallis tests, with appropriate post-hoc tests (Dunn's
test). Correlations were assessed using Spearman’s rank correlation coefficient. For the avoid-
ance of type I errors during the performance of multiple correlations we have used the correc-
tion method described by Benjamini and Hochberg (1995)[46] according to which a p-
value<0.023 was considered statistically significant. Group data are expressed as mean±SD or
as median (interquartile ranges) for normally distributed and skewed data, respectively. Kaplan
Meier Curves were created in order to compare survival in patients with low and those with ele-
vated SP levels and the groups were compared using Log Rank test. The 75th percentile of each
SP was used as a cut-off point in order to divide the patients in those with elevated SP levels
and those with non-elevated SP levels. Graphical presentations of times to events were per-
formed with Kaplan-Meier curves. Results are presented as hazard ratios (HR) with 95% confi-
dence intervals (CI). With the exception of the multiple correlations, all other p-values<0.05
were considered statistically significant. Analysis was performed using SPSS 17 statistical pack-
age (SPSS, Chicago, IL) and GraphPad Prism 5 (GraphPad Software Inc, La Jolla, CA, USA).
Results
We evaluated 184 consecutive patients with either emphysema, IPF and CPFE and 122 of them
were eligible to be included in the present study. The flow chart of the study participants is
shown in Fig 1. An additional 25 healthy subjects (smokers and non-smokers) were included
as healthy controls. The demographic and functional characteristics as well as serum levels of
surfactant proteins of the 122 patients and 25 healthy controls included in the study are pre-
sented in Table 1. Serum SP-A and SP-D levels significantly differed between groups (p = 0.006
and p<0.001 for SP-A and SP-D, respectively; Fig 2A–2D). In post-hoc analysis, SP-A levels
differed significantly only between controls and CPFE (p<0.05) and between CPFE and
Surfactant Proteins in CPFE
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emphysema (p<0.05). Similarly, post hoc analysis regarding serum SP-D levels revealed signif-
icant differences between controls and fibrosis or CPFE as well as emphysema and fibrosis or
CPFE (p<0.001 for all comparisons).
Correlations of surfactant proteins and pulmonary function tests
Correlations of surfactant proteins and pulmonary function are shown in Table 2. In patients
with fibrosis serum SP-B levels correlated significantly to pulmonary function test results, and
specifically to FEV1, FVC, DLCO, TLC, and FRC. The CPI presented only a weak correlation
with SP-A (p = 0.016; Fig 3A–3D).
SP levels as predictors of survival
There were limited deaths during the 1-year follow-up in this study, including 8 patients with
IPF and 1 patient with emphysema, whereas no control subjects and no patients with CPFE
died during the 1-year follow up. Therefore, the potential predictive role of SP levels on survival
was evaluated only in patients with IPF. We have evaluated the role of SP levels as predictors of
survival in our patients using the 75th percentiles levels as cut-off points, specifically SP-A
280ng/mL, SP-B26ng/mL, SP-C1.9 ng/mL, and SP-D287ng/mL. In patients with IPF,
SP-B levels above the 75th percentile of 26 ng/mL were associated with increased mortality
(p = 0.05 Log rank test; Fig 4). The levels of SP-A, C and D were not related to survival in
patients with IPF (p = 0.642, p = 0.632 and p = 0.623 for SP-A, SP-C and SP-D respectively).
Fig 1. Flow chart showing subjects who were finally included to the study.
doi:10.1371/journal.pone.0157789.g001
Surfactant Proteins in CPFE
PLOSONE | DOI:10.1371/journal.pone.0157789 June 23, 2016 5 / 18
The effect of smoking on SP levels
Smoking seemed to influence serum SP-A and SP-D levels only in control subjects. Current
smokers had higher serum SP-A and SP-D levels compared to current non-smokers (both
never smokers and ex-smokers) [325.7 (152.6, 357.0) vs 156.3 (104.0, 188.2), p = 0.026] and
[41.0 (14.3, 110.2) vs 10.4 (5.6, 33.3), p = 0.023 for SP-A and SP-D, respectively]. No differences
were observed according to smoking habit regarding SP-B (p = 0.300) and SP-C (p = 0.508)
levels (Fig 5A–5D). Furthermore, no significant differences of serum levels of any of the four
SPs have been found according to current smoking habit in patients with emphysema, fibrosis
or CPFE (data not shown).
The effect of the extend of fibrosis on SP levels
CPFE patients were divided in two subgroups according to the presence of significant extent of
emphysematous lesions: 23 patients were considered to have significant emphysematous
lesions (i.e.15% of total lung area) whereas 6 patients had emphysematous lesions<15%.
SP-D levels were significantly higher in CPFE patients with significant extent of emphysema
compared to those without significant extent of emphysema [290.7 (195.5, 334.7) vs 191.5
(37.65, 244.5), p = 0.042] for CPFE patients with and without significant extent of emphysema-
tous lesions respectively (Fig 6). SP-A, SP-B and SP-D levels did not differ between these two
groups (p = 0.569, p = 0.309, and p = 0.969 respectively).
Table 1. Demographic and functional characteristics of the study participants.
Controls N = 25 Emphysema only
N = 31
IPF only N = 62 CPFE N = 29 p value
Age (years) 64.0(55.5, 67.5) 66.0 (59.0, 71.0) 72.0 (66.8, 78.0) 75.0 (63.0, 77.0) <0.001
Gender (Female) N(%) 14 (56.0%) 7 (22.6%) 19 (30.6%) 3 (10.3%) 0.002
BMI kg/m2 26.7 (24.5, 29.5) 24.9 (21.5, 26.8) 27.2 (24.5, 29.6) 27.9 (23.6, 29.1) 0.005
Smoking (current/ex/
never)
9/5/11 18/13/0 5/30/27 5/22/2 <0.001
Pys 10.0 (0.0, 35.0) 70.0 (40.0, 95.0) 12.5 (0.0, 36.0) 50.0 (30.0, 75.0) <0.001
FEV1 (%pred) 92.0 (87.5, 99.0) 56.4 (33.7, 79.6) 76.4 (65.5, 88.1) 76.3 (69.5, 98.0) <0.001
FVC (%pred) 90.0 (82.0, 93.5) 72.8 (60.1, 93.7) 68.3 (57.9, 82.1) 68.5 (60.3, 94.1) 0.001
FEV1/FVC 82.0 (78.5, 85.2) 54.4 (40.4, 69.0) 85.7 (81.3, 90.8) 79.0 (74.4, 86.7) <0.001
DLCO (%pred) 85.0 (82.0, 88.0) 52.4 (36.5, 72.0) 46.8 (35.2, 62.9) 32.0 (22.8, 46.4) <0.001
TLC (%pred) 85.0 (82.0, 87.5) 93.0 (81.2, 105.8) 59.1 (50.2, 73.2) 63.4 (56.5, 78.5) <0.001
RV (%pred) 83.0 (80.5, 88.0) 119.0 (90.3, 126.5) 54.9 (43.1, 67.4) 57.4 (47.9, 80.5) <0.001
FRC (%pred) 83.0 (81.0, 88.5) 100.0 (83.1, 129.8) 60.7 (52.9, 77.1) 67.0 (53.5, 80.0) <0.001
PO2/FiO2 390.5 (380.9, 392.9) 333.3 (300.0, 371.4) 352.4 (321.4, 3711.4) 285.7 (258.6, 350.0) <0.001
6MWD (m) 550.0 (497.5, 551.0) 455.0 (300.0, 515.0) 459.5 (330.0, 500.8) 207.0 (100.0, 424.5) <0.001
DLA (%) N/A 1.68 (0.6, 2.9) 1.5 (1.14, 2.2) 2.4 (1.75, 3.3) 0.001
CPI 20.9 (17.7, 24.9) 36.5 (21.4, 51.4) 49.4 (36.6, 60.2) 57.2 (48.3, 63.4) <0.001
SP-A (ng/ml) 180.4 (118.9, 285.2) 193.9 (105.8, 257.6) 218.0 (148.5, 293.2) 251.2 (225.9, 314.1) 0.006
SP-B (ng/ml) 14.3 (6.6, 21.3) 17.6 (7.2, 26.3) 17.9 (10.7, 25.9) 18.4 (11.9, 27.3) 0.353
SP-C (ng/ml) 1.4 (0.8, 2.2) 1.3 (0.7, 2.0) 1.2 (0.9, 1.8) 1.1 (0.8, 2.1) 0.925
SP-D (ng/ml) 17.0 (7.1, 43.6) 35.2 (19.1, 70.1) 259.8 (196.7, 333.2) 250.7 (181.8, 321.0) <0.001
Abbreviations: BMI: Body Mass Index, FEV1: Forced expiratory Volume in one Second, FVC: Forced Exhaled Vital Capacity, DLCO: Diffusing Capacity for
Carbon Monoxide, TLC: Total Lung Capacity, FRC: Functional Residual Capacity, RV: Residual Volume, 6MWD: 6 Minute Walking Distance, DLA:
Destructed Lung Area, CPI: Composite Physiological Index, SP: Surfactant Protein, IPF: Idiopathic Pulmonary Fibrosis, CPFE: Combined Pulmonary
Fibrosis and Emphysema. Bold represent statistically significant differences.
doi:10.1371/journal.pone.0157789.t001
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Discussion
In this study we have shown that the levels of SP-A and SP-D differ between controls, patients
with emphysema, IPF and CPFE, with IPF and CPFE demonstrating the highest values. Serum
SP-D levels were also significantly higher in CPFE patients with significant emphysematous
component. In patients with IPF serum SP-A, levels significantly correlated also to CPI a com-
posite index of estimation of disease severity and extent. Furthermore, serum SP-A and SP-D
levels were increased in healthy smokers compared to non-smokers. Finally, although SP-B did
not differ between groups its blood levels in patients with IPF correlated to FEV1, FVC, DLCO,
FRC and TLC and patients in the upper quartile of SP-B values were associated with worse sur-
vival. To our knowledge, this is the first study examining the possible differences of the levels
of the four SPs in these four groups of patients.
Regarding SP-A and SP-D, our findings confirm previous studies that have shown increased
levels in the circulation [24] of patients with fibrosis, although these levels were decreased in
the BAL fluid [22, 47] but without a significant association between the circulating levels of
these proteins and the extent of fibrosis in radiographic studies, a finding that was also
Fig 2. Serum surfactant protein levels in the different study groups. A. SP-A, B. SP-B, C. SP-C, D. SP-D.
doi:10.1371/journal.pone.0157789.g002
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confirmed in our study. Our finding that serum SP-A and SP-D levels are higher in patients
with fibrosis (IPF or CPFE) compared to those with only emphysema, suggests that the combi-
nation of alveolar parenchymal derangement that characterizes fibrosis with the hyperplasia of
type II alveolar cells [48], may lead to the translocation of greater amounts of these SPs from
the lung parenchyma to the peripheral circulation through the pulmonary vasculature in these
patients.
However, the fact that patients with CPFE and more extensive emphysematous lesions in
HRCT also expressed significantly higher levels of both SP-A and SP-D, might suggest that the
emphysematous component on top of the fibrotic process, stretched and overdistended by the
nearby fibrotic lesions, also contributes through an alveolar damage to the elevation of SP levels
in these patients [49–51]. Interestingly, in our study circulating levels of SP-A, correlated to
CPI in patients with IPF, CPI being a composite score found to be an important indicator of
the total respiratory impairment in IPF and related to the total extent of fibrosis in these
patients [37]. Although in patients with fibrosis, CPI has been acknowledged as a predictor of
Fig 3. Composite Physiological Index (CPI) correlations to A. SP-A, B. SP-B, C. SP-C and D: SP-D. Level of statistical significance after correction
for multiple correlation analysis was set at p < 0.023.
doi:10.1371/journal.pone.0157789.g003
Surfactant Proteins in CPFE
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survival, this was not the case in patients with CPFE [36], which probably explains the lack of
any significant correlation of SPs with CPI in this group in our study.
Furthermore, in our control group, we have observed that healthy current smokers had
higher serum levels of SP-A and SP-D compared to current non-smokers (including both
never and ex-smokers). This is in accordance to previous studies showing that smokers had
decreased levels of SP-A and SP-D in the bronchoalveolar lavage (BAL) fluid [52] although
they seemed to express higher circulating levels of the former [53]. A possible explanation of
these findings was that smokers may present an alveolo-capillary leakage of surfactant proteins
into the blood [54]. The fact that serum levels of SP-A are higher in current smokers compared
to ex-smokers [55], also observed in our cohort, might also represent the ongoing lung inflam-
mation caused by cigarette smoke which leads to increased vascular permeability and to SP-A
and SP-D translocation from the pulmonary compartment to the circulation [56]. It is known
that smoking cessation seems to rapidly restore the alveolar-capillary barrier integrity [57] and
this is probably the reason why healthy ex-smokers presented with similar serum levels of
Fig 4. Kaplan-Meier curve showing survival of patients with IPF according to the levels of SP-B.
doi:10.1371/journal.pone.0157789.g004
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SP-A and SP-D. However, this was not the case in patients with emphysema, fibrosis or CPFE
in which circulating SP levels did not differ between current smokers and current non-smokers
and it seems that the established lung inflammation in both pulmonary emphysema [58–61]
and fibrosis [62–65] continues despite smoking cessation. Increased serum SP-A and SP-D lev-
els in current smokers might be an early indicator of an ongoing parenchymal damage which
might lead to the development of lung disease.
Regarding SP-B, although its blood levels did not differ among groups, in patients with
fibrosis we found a correlation with both individual indices of disease severity and extent such
as FVC and DLCO, and in addition a marginal difference in survival, with patients with SP-B
levels at the higher quartile presenting lower survival. This finding is in accordance to previous
studies showing the relation of SP-B with the development of interstitial lung disease in both
animals [66] and humans [67]. FVC and DLCO are known to be significant predictors of sur-
vival in IPF [68, 69] and this might explain the weak association between serum SP-B levels
and mortality in this group of patients in our study. The mortality findings related to the
increased SP-B levels, however, need to be further validated in larger studies.
Fig 5. Serum surfactant protein levels in control subjects according to current smoking habit (current non-smokers N = 16 and
current smokers N = 9). A. SP-A, B. SP-B, C. SP-C, D. SP-D.
doi:10.1371/journal.pone.0157789.g005
Surfactant Proteins in CPFE
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Finally regarding SP-C there is some evidence that might play a role in the development of
CPFE [30, 31] and patients with lung disease comparable with CPFE were found to have muta-
tions in the SP-C gene [32, 33]. It is important to mention that in our group of patients, serum
levels of SP-C did not differ in patients with CPFE and were not associated with any disease
characteristic including pulmonary function impairment, and the extent of fibrosis. The lack of
such an association might relate to fact that SP-C gene mutations possibly result to functional
rather than quantitative alterations of SP-C [70].
Our study has significant limitations. First, we have used an observational method for the
quantification of fibrosis and/or emphysema in HRCT, instead of dedicated CT software. How-
ever, this method presents excellent correlation with densitometry quantitation [39, 40] and
can be performed in everyday clinical practice. Second, patients were followed up for only one
year which is probably the reason for the lack for any significant associations regarding SPs
and survival in patients with emphysema and CPFE. Finally, it is a fact that SP-A and SP-D are
additionally produced in several extrapulmonary locations, including the brain, the salivary
Fig 6. Serum Surfactant Protein levels in CPFE patients according to the extent of emphysematous lesions.
doi:10.1371/journal.pone.0157789.g006
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glands, the heart, the kidneys and the reproductive tract [71] and for this reason we cannot
confirm that the levels that are measured in serum directly originate from the lung. However,
since the greater amounts of all four surfactant proteins are synthesized by alveolar type II cells
and SP-A, SP-B and SP-D are also produced by different types of airway cells, including Clara
cells and submucosal cells, we can conclude that the major source of serum SP levels comes
from the pulmonary epithelium.
In conclusion, in this study including controls, emphysema, IPF, and CPFE patients we
have shown that serum SP- A and SP-D present significantly higher serum levels where fibrosis
exists or coexists while serum SP-A levels are also related to fibrosis severity and extent as
reflected by the CPI score of estimation of disease severity. The above findings might suggest
that serum SP-A and SP-D levels are related to the type of alveolar damage installed on fibrotic
lungs and reflect their overproduction due to hyperplasia of type II alveolar cells, or overleak-
age in the systemic circulation caused by alveolar basement membrane splintering off and
hyperpermeability. In IPF also SP-B relates to survival. Further studies are needed to define the
role of the above SPs as markers of disease severity.
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